VivoSeq
29

Pipeline Programs

4

Active Trials

14

Companies Involved

Gastritis is an emerging landscape with 29 programs across 14 companies. The most active players are Moderna, AbbVie, Yooyoung Pharmaceutical Co., Ltd.. 12 therapies are approved with 5 more in late-stage development.

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

11/100

Mech. Concentration

50/100

Completion Rate

92/100

Attrition Rate

4/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

95%

Small molecule

38 of 40 classified programs — the dominant modality here.

5%ALL OTHERSMonoclonal antibody13%Cell therapy13%

Small molecule leads; the ring shows all 40 classified programs, each share of the total. Modality classified for 100% of 41 pipeline programs.

Trial Status

25

clinical trials

Completed12 · 48%
Unknown status8 · 32%
Not yet recruiting2 · 8%
Active, not recruiting2 · 8%
Terminated1 · 4%

Trial Activity

25 trials

Vedolizumab for the Treatment of Collagenous Gastritis
Active, not recruiting·MMassachusetts General Hospital·Phase 2·NCT06317220·11 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)